Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday
For the most part, U.S. stocks had a good Monday, with the bellwether S&P 500 index confidently marching more than 1% higher. But BioCryst Pharmaceuticals (NASDAQ: BCRX) and its investors had a really good day, as the company delivered a first quarter that convincingly beat analyst estimates.
The market rewarded this performance by pushing BioCryst's share price more than 18% higher on the day.
A double beat in the opening quarter of 2024
BioCryst showed some solid growth numbers in that earnings report. For the quarter, it earned just under $93 million in total revenue, which was nearly 35% higher on a year-over-year basis. In terms of debits from the profit and loss statement, the pharmaceutical company managed to shave its all-important research and development expenses by almost $2 million thanks to discontinuations and out-licensing activities with several pipeline drugs.
As for the bottom line, BioCryst did a good job of narrowing its net loss. On both a generally accepted accounting principles (GAAP) and non-GAAP (adjusted) basis, this was a much slimmer $35 million ($0.17) per share compared to first quarter 2023's more than $53 million shortfall.
Those headline figures both convincingly beat the analyst consensus. On average, pundits following the stock were modeling just under $86 million on the top line, and a steeper $0.21 per share for net loss.
Nearly all of BioCryst's revenue comprises sales of Orladeyo, which treats the swelling disorder hereditary angioedema. The company said in its earnings release that it is seeing strong patient demand for the drug; adding to this, it anticipates advancing several of its investigational drugs into clinical testing.
Orladeyo should continue to lead the way
BioCryst also adjusted its guidance for the entirety of 2024. On the back of that demand, it's now expecting Orladeyo sales to come in at $390 million to $400 million. It added without elaboration that it will achieve an operating profit this year, and "be approaching," both positive earnings per share and cash flow in the second half of 2025.
Should you invest $1,000 in BioCryst Pharmaceuticals right now?
Before you buy stock in BioCryst Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BioCryst Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $544,015!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of May 6, 2024
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday was originally published by The Motley Fool